Letrozole and Anastrozole in Early Breast Cancer Post-menopausal Patients in Oncology Department at Suez Canal University Hospital

Abstract

Background:There are limited data in the literature comparing the efficacy of aromatase inhibitors in postmenopausal hormonal receptor positive early breast cancer patients. Aim: To compare the efficacy of letrozole and anastrozole in hormone-receptor positive postmenopausal breast cancer patients. Patients and Methods: A retrospective study with a mean follow-up period of 64 months (about 5 years) for 74 files of early invasive postmenopausal breast cancer hormonal receptor positive patients; 39 received letrozole and 35 received anastrozole, considering TTP as primary end point, and OS as second end points. Results: Letrozole is not superior to anastrozole during the first 55 months of treatment (80% PFS at 5 th year), and 80% OS benefit at 6 th year.. Overweight patients had better (90% PFS at 5 th year) than obese patients (60% PFS at 5 th year). Conclusion: Letrozole is not superior to anastrozole in efficacy in early invasive hormonal receptor positive breast cancer postmenopausal patients during the first 5 years of treatment; however, Letrozole 2 nd line after tamoxifen is superior to anastrozole 2 nd line after tamoxifen in treating obese patients with early invasive hormone receptor positive breast cancer.